Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Metastatic Anal Canal Cancer, Human Papillomavirus
Both
Metastatic Anal Canal Cancer, Human Papillomavirus
Trial Information
Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal
Inclusion Criteria:
- ECOG performance status ≤ 1
- patient with metastatic anal cancer HPV+
- presence of a measurable target lesion according to radiological criteria (Recist
V1.1)
- patient with more than 12 months of complete remission of metastatic anal cancer
according to radiological criteria (Recist V1.1)after treatment by DCF regimen
(Docetaxel, Cisplatin and 5-Fluorouracil)
Exclusion Criteria:
- pregnancy or lactation
- patient with any medical or psychiatric condition or disease which would make the
patient inappropriate for entry into this study.
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
presence and characterization of anti-HPV immune responses in patients in complete remission
Outcome Time Frame:
3 months after sample
Safety Issue:
No
Authority:
France: Committee for the Protection of Person
Study ID:
Epitope-HPV01
NCT ID:
NCT01845779
Start Date:
September 2012
Completion Date:
September 2015
Related Keywords:
- Metastatic Anal Canal Cancer
- Human Papillomavirus
- Neoplasm Metastasis
- Anus Neoplasms
Name | Location |
|---|
